Feb. 26—On Friday, Johnson & Johnson received the go-ahead for Emergency Use Authorization for their single-dose COVID-19 vaccine for adults 18 and older from an advisory panel to the United States Food and Drug Administration. With efficacy of 72% in U.S. trials, this will be the third vaccine available, joining the Pfizer and Moderna mRNA shots. In contrast to the required freezer storage ...